CorMedix Inc.
CRMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001410098
No open-market purchases or sales by CorMedix Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $345.5M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +7 vs. previous quarter
- 193
- 13F valueReported value at the end of Q2 2026
- $345.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CRMD, Q2 2026
No superinvestor reported holding CRMD at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by CorMedix Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Dillione JanetDirector | SSale | −10.0K | $6.88 | −$68.8K | −20.6%38.5K after | 10b5-1 |
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Dunton Alan WDirector | SSale | −20.0K | $13.00 | −$260.0K | −33.2%40.3K after | 10b5-1 |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Todisco JosephChief Executive Officer | SSale | −30.0K | $12.00 | −$360.0K | −5.6%509.5K after | 10b5-1 |
| Dec 11, 2025 (view filing) | Dec 9 | 2 days | Dillione JanetDirector | SSale | −34.0K | $12.00 | −$408.0K | −41.2%48.5K after | 10b5-1 |
| Dec 10, 2025 (view filing) | Dec 9 | 1 day | Lefkowitz Steven WDirector | SSale | −40.0K | $11.88 | −$475.2K | −33.2%80.5K after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Dillione JanetDirector | SSale | −46.7K | $10.00 | −$466.6K | −49.0%48.5K after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Dillione JanetDirector | SSale | −26.3K | $9.93 | −$261.6K | −35.2%48.5K after | |
| Nov 18, 2025 (view filing) | Nov 14 | 4 days | Dillione JanetDirector | SSale | −30.0K | $11.42 | −$342.6K | −38.2%48.5K after | |
| Oct 27, 2025 (view filing) | Oct 23 | 4 days | Kaplan MyronDirector | PPurchase | +25.0K | $11.02 | +$275.5K | +14.2%201.0K after | |
| Sep 16, 2025 (view filing) | Sep 12 | 4 days | Dunton Alan WDirector | SSale | −10.0K | $13.13 | −$131.3K | −19.9%40.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in CorMedix Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,324,111 | $49.6M | 0.00% | +356,536+6.0% | Added |
| Deep Track Capital, LP | 6,274,076 | $49.3M | 0.73% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 3,135,075 | $24.6M | 0.00% | +5,419+0.2% | Added |
| State Street Corp | 2,316,845 | $18.2M | 0.00% | +125,002+5.7% | Added |
| Royce & Associates LP | 2,176,362 | $17.1M | 0.14% | +288,830+15.3% | Added |
| Geode Capital Management, LLC | 1,947,014 | $15.3M | 0.00% | +130,107+7.2% | Added |
| UBS Group AG | 1,877,940 | $14.7M | 0.00% | +339,695+22.1% | Added |
| Oberweis Asset Management Inc | 1,323,915 | $10.4M | 0.21% | +112,800+9.3% | Added |
| Alyeska Investment Group, L.P. | 850,000 | $6.67M | 0.02% | 00.0% | Unchanged |
| Marshall Wace, LLP | 779,535 | $6.12M | 0.01% | +276,570+55.0% | Added |